Posted by Michael Wonder on 25 Jul 2017
Vismodegib for treatment of patients with basal cell carcinoma
20 July 2017 - The Department of Health has asked the NICE to produce guidance on the use vismodegib in the NHS in England.
Vismodegib is not recommended within its marketing authorisation for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy, in adults.
Vismodegib will be considered at a second appraisal committee meeting on 30 August 2017.
